RGEN. Regeneron Reports Third Quarter 2012 Financial and Operating Results
-- Third quarter EYLEA® (aflibercept) Injection sales increased 26% over second quarter to $244 million
-- Full year 2012 EYLEA U.S. sales forecast increased from $700 - $750 million to $790 - $815 million
-- Third quarter non-GAAP profit climbs to $217 million or $1.89 per diluted share
http://finance.yahoo.com/news/regeneron-reports-third-quarter-2012-103000608.html
-- Third quarter EYLEA® (aflibercept) Injection sales increased 26% over second quarter to $244 million
-- Full year 2012 EYLEA U.S. sales forecast increased from $700 - $750 million to $790 - $815 million
-- Third quarter non-GAAP profit climbs to $217 million or $1.89 per diluted share
http://finance.yahoo.com/news/regeneron-reports-third-quarter-2012-103000608.html
Index Prime
http://investorshub.advfn.com/Index-Prime-25623/
5-bagger contest on Dawgg.
http://investorshub.advfn.com/%22Dawgg%22-21519/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
